Top

CNS Drugs

Published in:

01-09-2003 | Review Article

Effect of Antiepileptic Drugs on Bodyweight

Overview and Clinical Implications for the Treatment of Epilepsy

Author: Dr Victor Biton

Published in: CNS Drugs | Issue 11/2003

Abstract

The potential of specific antiepileptic drugs (AEDs) to cause clinically significant changes in bodyweight is a key consideration in the management of epilepsy; changes in weight can pose health hazards, impair body image and self-esteem, and lead to noncompliance with therapy. This article reviews the data regarding the effects of conventional and newer AEDs on weight and discusses the clinical implications of these effects for the management of patients with epilepsy. The data demonstrate that AEDs can differ substantially in their effects on weight. Some, such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it. Still others, such as lamotrigine, levetiracetam and phenytoin, are weight neutral.

Because most data regarding the effects of AEDs on weight are circumstantial, the incidence, magnitude and determinants of weight changes with AEDs remain poorly elucidated. Furthermore, little is known about the mechanisms of AED-induced changes in weight.

The importance of effects on weight in selecting an AED depends largely upon the individual patient’s needs and the risks and benefits of therapy for that patient. The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise.

Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22: 27–39PubMedCrossRef

Foster D. Gain and loss in weight. In: Fauci S, editor. Harrison’s principles of internal medicine. 14th ed. New York: McGraw Hill, 1998

Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842–7PubMedCrossRef

Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24: 969–78PubMedCrossRef

McGinnis J, Foege W. Actual causes of death in the United States. JAMA 1993; 270: 2207–12PubMedCrossRef

Burton BR, Foster WR, Hirsch J, et al. Health implications of obesity: NIH consensus development conference. Int J Obes Relat Metab Disord 1985; 9: 155–69

Schmidt D. Adverse effects of valproate. Epilepsia 1984; 25Suppl. 1: S44–9PubMedCrossRef

Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240–4PubMed

Easter D, O’Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine: a reappraisal. Seizure 1997; 6: 121–5PubMedCrossRef

10.

Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283: 577–81PubMedCrossRef

11.

Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 69: 65–9CrossRef

12.

Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–84PubMedCrossRef

13.

Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999; 14: 490–5PubMedCrossRef

14.

Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230–2PubMedCrossRef

15.

Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000; 22: 361–4PubMedCrossRef

16.

Vainionpaa LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444–50PubMedCrossRef

17.

Isojärvi JIT, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000; 57: 1064–8PubMedCrossRef

18.

Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRef

19.

Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835–41PubMedCrossRef

20.

Pijl H, Meinders AE. Bodyweight changes as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996; 14: 329–42PubMedCrossRef

21.

Mattson TH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–71PubMedCrossRef

22.

Richens A, Davidson DLW, Cartlidge NEF, et al. A multicenter comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–7PubMedCrossRef

23.

Verity CM, Hosking G, Easter DJ, et al. A multicenter comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97–108PubMedCrossRef

24.

Aston MG, Ball SG, Thomas LH, et al. Water intoxication associated with carbamazepine treatment. BMJ 1977; 1: 1134–5CrossRef

25.

Lampl Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14: 251–5PubMedCrossRef

26.

Kimura T, Matsui K, Sato T, et al. Mechanism of carbamazepine-induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 1974; 38: 356–62PubMedCrossRef

27.

Meinders AE, Cejka V, Robertson G. The antidiuretic action of carbamazepine in man. Clin Sci Mol Med 1974; 47: 289–99PubMed

28.

Sorensen PS, Hammer M. Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. EurJ Clin Pharmacol 1984; 26: 719–22CrossRef

29.

Krause KH, Rascher W, Berlit P. Plasma arginine vasopressin concentrations in epileptics under monotherapy. J Neurol 1983; 230: 193–6PubMedCrossRef

30.

Garofalo EA, Hartman T, Hayes A, et al. Weight changes during a gabapentin 26-week monotherapy trial [abstract 6.34]. Epilepsia 1996; 37 Suppl. 5: 160

31.

King JA, Bayles RL. Weight gain during add-on therapy using gabapentin [abstract 3.60]. Epilepsia 1995; 36 Suppl. 4: 72

32.

Asconape J, Collins T. Weight gain associated with the use of gabapentin [abstract 3.58]. Epilepsia 1995; 36 Suppl. 4: 72

33.

Gidal BE, Maly MM, Nemire RE, et al. Weight gain and gabapentin therapy [letter]. Ann Pharmacother 1995; 29: 1048PubMed

34.

DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6PubMedCrossRef

35.

Cahill WT, Mozahem K, Privitera MD. Weight changes with the use of gabapentin [abstract 2.090]. Epilepsia 1998; 39 Suppl. 6: 54

36.

Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992; 15: 491–7PubMedCrossRef

37.

Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of the refractory epilepsy. Br J Clin Pharmacol 1989; 27Suppl. 1: S125–9CrossRef

38.

Tartara A, Manni R, Galimberti CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992; 96: 247–51CrossRef

39.

Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicenter randomised double-blind study. Lancet 1999; 354: 13–9PubMedCrossRef

40.

Guberman A, Bruni J. Long-term open multicenter, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9: 112–8PubMedCrossRef

41.

Uldall P, Alving J, Gram L, et al. Vigabatrin in childhoodepilepsy: a 5-year follow-up study. Neuropediatrics 1995; 26:253–6PubMedCrossRef

42.

Guberman A. Vigabatrin. Can J Neurol Sci 1996; 23: S13–7PubMed

43.

Pellock JM, Morton LD. Treatment of epilepsy in the multi-handicapped. Ment Retard Dev Disabil Res Rev 2000; 6: 309–23PubMedCrossRef

44.

Coppola G, Caliendo G, Terracciano MM, et al. Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res 2001; 43: 255–60PubMedCrossRef

45.

Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000; 15Suppl. 1: S22–6PubMedCrossRef

46.

Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977–80PubMedCrossRef

47.

Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizures 2000; 9: 137–41CrossRef

48.

Ben-Menachem E, Smith U, Hellstrom K, et al. Prospective study on metabolism and weight changes in patients with epilepsy treated with topiramate [abstract]. Epilepsia 2000; 41Suppl. 7: 222

49.

Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000; 34: 1262–4PubMedCrossRef

50.

Erfurth A, Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology 2000; 42 Suppl. 1: 50–1CrossRef

51.

Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40: 1364PubMedCrossRef

52.

Chengappa KNR, Levine J, Rathore D, et al. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186–90CrossRef

53.

Shuaib A, Ahmad F, Kochanski P, et al. Efficacy of topiramate in prophylaxis of frequent severe migraines or chronic daily headaches: experience with 70 patients over 18 months [abstract]. Cephalalgia 2000; 20: 423

54.

Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in prophylactic treatment of migraines in patients refractory to preventative intervention: a retrospective chart review in a tertiary clinic [abstract]. Cephalalgia 2000; 20: 423

55.

Wilson MC. Efficacy of topiramate in the prophylactic treatment of intractable chronic migraine: retrospective chart review [abstract]. Cephalalgia 2000; 20: 301

56.

Edwards KR, Glantz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [abstract]. Neurology 2000; 54Suppl. 3: A81

57.

Brown RO, Orr CD, Hanna DL, et al. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy 2002; 22: 831–5PubMedCrossRef

58.

Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961–6PubMedCrossRef

59.

Carmant L, Holmes GL, Sawyer S, et al. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994; 125: 481–6PubMedCrossRef

60.

Graves NM. Felbamate. Ann Pharmacother 1993; 27: 1073–81PubMed

61.

Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001; 47: 1–7PubMedCrossRef

62.

Felbatol (felbamate) package insert. Cranbury (NJ): Wallace Laboratories, 1999

63.

Bergen DC, Ristanovic RK, Waicosky K, et al. Weight loss in patients taking felbamate. Clin Neuropharmacol 1995; 18: 23–7PubMedCrossRef

64.

Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9PubMedCrossRef

65.

Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration. Oxford: Oxford Update Software, 2002: CD001416

66.

Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin, with sodium valproate: a randomized, double-blind study. Indian Pediatr 1996; 33: 549–55PubMed

67.

Finkel MJ. Phenytoin revisited. Clin Ther 1984; 6: 577–91PubMed

68.

Hayes G, Kootsikas ME. Reassessing the lower end of the phenytoin therapeutic range: a review of the literature. Ann Pharmacother 1993; 27: 1389–92PubMed

69.

Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–7PubMedCrossRef

70.

Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5PubMedCrossRef

71.

Ueberall MA. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients: a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001; 46: 63–7PubMedCrossRef

72.

Gidal B, Sheth R, Maganti R, et al. Levetiracetam weight change during placebo-controlled clinical trials [abstract]. Epilepsia 2001; 42Suppl. 7: 157

73.

Loiseau P. Review of controlled trials of Gabitril: a clinician’s viewpoint. Epilepsia 1999; 40Suppl. 9: S14–9PubMedCrossRef

74.

Hogan RE, Bertrand ME, Deaton RL, et al. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine, and phenytoin. Epilepsy Res 2000; 41: 23–8PubMedCrossRef

75.

Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15(2): 137–63PubMedCrossRef

76.

Rattya J, Vainionpaa L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588–93PubMedCrossRef

Title: Effect of Antiepileptic Drugs on Bodyweight
Overview and Clinical Implications for the Treatment of Epilepsy
Author: Dr Victor Biton
Publication date: 01-09-2003
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 11/2003
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200317110-00002

2024 ASCO Annual Meeting

Springer Medicine

Effect of Antiepileptic Drugs on Bodyweight

Overview and Clinical Implications for the Treatment of Epilepsy

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2003

Pharmacological Management of Postherpetic Neuralgia

Tolerability and Consistency of Effect of Zolmitriptan Nasal Spray in a Long-Term Migraine Treatment Trial

Benzodiazepines and Risk of Hip Fractures in Older People

Management of the Negative Symptoms of Schizophrenia